Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

An investigation of asymmetric reduction in dopamine transporter density in patients with Parkinson's disease.

Okizaki A, Yamamoto W, Saito W, Miyano T, Kimura T, Suzuki Y, Nakayama M.

Nucl Med Commun. 2019 Sep 26. doi: 10.1097/MNM.0000000000001087. [Epub ahead of print]

PMID:
31568269
2.

Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study

Matsumura A, Miyazaki T, Tachibana T, Ando T, Koyama M, Koyama S, Ishii Y, Takahashi H, Nakajima Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S, Nakajima H.

Turk J Haematol. 2019 Aug 29. doi: 10.4274/tjh.galenos.2019.2019.0139. [Epub ahead of print]

3.

Utility and Validity of Intracoronary Administration of Nicorandil Alone for the Measurement of Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis.

Ishibuchi K, Fujii K, Otsuji S, Takiuchi S, Hasegawa K, Tamaru H, Ishii R, Yasuda S, Nakabayashi S, Yamamoto W, Kusumoto H, Taniguchi Y, Kakishita M, Shimatani Y, Higashino Y.

Circ J. 2019 Sep 25;83(10):2010-2016. doi: 10.1253/circj.CJ-19-0421. Epub 2019 Aug 14.

4.

Optical coherence tomography characteristics of in-stent restenosis after drug-eluting stent implantation: a novel classification and its clinical significance.

Yamamoto W, Fujii K, Otsuji S, Takiuchi S, Kakishita M, Ibuki M, Hasegawa K, Ishibuchi K, Tamaru H, Yasuda S, Ishii R, Nakabayashi S, Kusumoto H, Higashino Y.

Heart Vessels. 2019 Jun 27. doi: 10.1007/s00380-019-01461-7. [Epub ahead of print]

PMID:
31250131
5.

Evaluation of risk factors for atherosclerosis using carotid ultrasonography in Japanese patients with rheumatoid arthritis.

Yamamoto H, Nakajima T, Kawahara R, Nakabo S, Hashimoto M, Yamamoto W, Masuda I, Ito H, Mimori T, Fujii Y.

Int J Rheum Dis. 2019 Jul;22(7):1312-1318. doi: 10.1111/1756-185X.13591. Epub 2019 May 17.

PMID:
31099177
6.

Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019.

7.

Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

Arthritis Res Ther. 2019 May 6;21(1):114. doi: 10.1186/s13075-019-1897-8.

8.

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

Arthritis Res Ther. 2019 Apr 11;21(1):91. doi: 10.1186/s13075-019-1880-4. Erratum in: Arthritis Res Ther. 2019 May 6;21(1):114.

9.

Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, Yamamoto W, Mimori T, Terao C.

Semin Arthritis Rheum. 2019 Oct;49(2):204-210. doi: 10.1016/j.semarthrit.2019.02.003. Epub 2019 Feb 10.

PMID:
30803720
10.

CD3+ B-1a Cells as a Mediator of Disease Progression in Autoimmune-Prone Mice.

Yamamoto W, Toyoda H, Xu DQ, Hanaki R, Morimoto M, Nakato D, Ito T, Iwamoto S, Bonno M, Tanaka S, Hirayama M.

Mediators Inflamm. 2018 Dec 23;2018:9289417. doi: 10.1155/2018/9289417. eCollection 2018.

11.

Endoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic β cell.

Yamamoto WR, Bone RN, Sohn P, Syed F, Reissaus CA, Mosley AL, Wijeratne AB, True JD, Tong X, Kono T, Evans-Molina C.

J Biol Chem. 2019 Jan 4;294(1):168-181. doi: 10.1074/jbc.RA118.005683. Epub 2018 Nov 12.

PMID:
30420428
12.

Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort.

Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, Yamamoto W, Mimori T, Matsuda S.

Int J Rheum Dis. 2019 Jun;22(6):1084-1093. doi: 10.1111/1756-185X.13428. Epub 2018 Nov 11.

PMID:
30415498
13.

Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.

Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, Tanaka M, Fujii T, Omura T, Imai S, Nakagawa T, Yonezawa A, Imai H, Mimori T, Matsubara K.

PLoS One. 2018 Nov 2;13(11):e0206943. doi: 10.1371/journal.pone.0206943. eCollection 2018.

14.

Evaluation of repeated progression of native coronary artery stenosis by optical frequency domain imaging in a patient with essential thrombocytosis.

Tamaru H, Fujii K, Otsuji S, Takiuchi S, Hasegawa K, Ishibuchi K, Ishii R, Yamamoto W, Nakabayashi S, Kakishita M, Ibuki M, Nagayama S, Higashino Y.

J Cardiol Cases. 2018 May 30;18(2):74-77. doi: 10.1016/j.jccase.2018.04.009. eCollection 2018 Aug.

15.

Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study.

Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M, Ito H, Fujii T, Tanaka M, Terao C, Kono H, Mori M, Hamaguchi M, Yamamoto W, Ohmura K, Morita S, Mimori T.

Scand J Rheumatol. 2019 Mar;48(2):87-94. doi: 10.1080/03009742.2018.1477989. Epub 2018 Sep 30.

PMID:
30269670
16.

Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis.

Tsuji H, Ikari K, Ohmura K, Yano K, Furu M, Hashimoto M, Ito H, Fujii T, Yamamoto W, Taniguchi A, Yamanaka H, Mimori T, Terao C.

Ann Rheum Dis. 2019 Feb;78(2):284-286. doi: 10.1136/annrheumdis-2018-214022. Epub 2018 Sep 19. No abstract available.

PMID:
30232193
17.

Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis.

Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, Uozumi R, Hamaguchi M, Terao C, Yamamoto W, Uda M, Nin K, Morita S, Arai H, Mimori T.

Mod Rheumatol. 2019 Jul;29(4):589-595. doi: 10.1080/14397595.2018.1510565. Epub 2018 Sep 11.

PMID:
30092163
18.

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.

Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T.

Arthritis Res Ther. 2018 Aug 3;20(1):165. doi: 10.1186/s13075-018-1673-1.

19.

Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study.

Yoshida T, Hashimoto M, Kawahara R, Yamamoto H, Tanaka M, Ito H, Masuda I, Hosoda K, Yamamoto W, Uozumi R, Morita S, Fujii Y, Mimori T, Nin K.

Rheumatol Int. 2018 Sep;38(9):1679-1689. doi: 10.1007/s00296-018-4095-0. Epub 2018 Jul 4.

20.

Persistence of vertebral growth plate cartilage in aged cynomolgus monkeys.

Iwata M, Yamamoto W, Shimomoto T, Okada Y, Oosawa S, Miura D, Hara Y.

J Toxicol Pathol. 2018 Apr;31(2):151-154. doi: 10.1293/tox.2017-0041. Epub 2018 Feb 10.

21.

Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study

Matsumoto K, Fujisawa S, Ando T, Koyama M, Koyama S, Ishii Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Nakajima H.

Turk J Haematol. 2018 Aug 3;35(3):181-184. doi: 10.4274/tjh.2017.0437. Epub 2018 Mar 28.

22.

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H.

PLoS One. 2018 Mar 15;13(3):e0194130. doi: 10.1371/journal.pone.0194130. eCollection 2018.

23.

Distinct roles for plasma membrane PtdIns(4)P and PtdIns(4,5)P2 during receptor-mediated endocytosis in yeast.

Yamamoto W, Wada S, Nagano M, Aoshima K, Siekhaus DE, Toshima JY, Toshima J.

J Cell Sci. 2018 Jan 4;131(1). pii: jcs207696. doi: 10.1242/jcs.207696.

24.

The Serum Level of KL-6 Is Associated with the Risk of Insulin Resistance and New-onset Diabetes Mellitus: The Tanno-Sobetsu Study.

Akasaka H, Ohnishi H, Narita Y, Kameda M, Miki T, Takahashi H, Yamamoto W, Sohma H, Masumori N, Miura T; SPRUCE project investigators.

Intern Med. 2017 Nov 15;56(22):3009-3018. doi: 10.2169/internalmedicine.8716-16. Epub 2017 Sep 25.

25.

Importance of the alignment of polar π conjugated molecules inside carbon nanotubes in determining second-order non-linear optical properties.

Yumura T, Yamamoto W.

Phys Chem Chem Phys. 2017 Sep 20;19(36):24819-24828. doi: 10.1039/c7cp03128a.

PMID:
28868534
26.

IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.

Takasugi K, Nishida K, Natsumeda M, Yamashita M, Yamamoto W, Ezawa K.

Mod Rheumatol. 2018 May;28(3):452-460. doi: 10.1080/14397595.2017.1361802. Epub 2017 Aug 22.

PMID:
28828944
27.

Time-averaged disease activity fits better joint destruction in rheumatoid arthritis.

Tsuji H, Yano K, Furu M, Yamakawa N, Ikari K, Hashimoto M, Ito H, Fujii T, Yamamoto W, Ohmura K, Taniguchi A, Momohara S, Matsuda F, Allaart CF, Yamanaka H, Mimori T, Terao C.

Sci Rep. 2017 Jul 19;7(1):5856. doi: 10.1038/s41598-017-05581-w.

28.

Accuracy of J-CTO Score Derived From Computed Tomography Versus Angiography to Predict Successful Percutaneous Coronary Intervention.

Fujino A, Otsuji S, Hasegawa K, Arita T, Takiuchi S, Fujii K, Yabuki M, Ibuki M, Nagayama S, Ishibuchi K, Kashiyama T, Ishii R, Tamaru H, Yamamoto W, Hara M, Higashino Y.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):209-217. doi: 10.1016/j.jcmg.2017.01.028. Epub 2017 Jun 14.

29.

The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Takahashi H, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Nakajima H, Miura I, Takeuchi K.

Leuk Lymphoma. 2018 Jan;59(1):97-104. doi: 10.1080/10428194.2017.1330541. Epub 2017 Jun 8.

PMID:
28593796
30.

CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.

Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:73-81. doi: 10.1016/j.vascn.2017.02.001. Epub 2017 Feb 3.

PMID:
28163191
31.

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.

Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, Tachibana T, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Fujita H, Kanamori H, Fujisawa S, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT).

Int J Hematol. 2017 May;105(5):623-630. doi: 10.1007/s12185-017-2183-7. Epub 2017 Jan 21.

PMID:
28110409
32.

Relationship between handedness and joint involvement in rheumatoid arthritis.

Yaku A, Hashimoto M, Furu M, Ito H, Yamakawa N, Yamamoto W, Fujii T, Matsuda F, Mimori T, Terao C.

Sci Rep. 2016 Dec 15;6:39180. doi: 10.1038/srep39180.

33.

A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.

Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y.

J Pharmacol Toxicol Methods. 2017 Mar - Apr;84:111-127. doi: 10.1016/j.vascn.2016.12.003. Epub 2016 Dec 10.

34.

Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.

Yamamoto W, Asakura K, Ando H, Taniguchi T, Ojima A, Uda T, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yoshinaga T, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y.

PLoS One. 2016 Dec 6;11(12):e0167348. doi: 10.1371/journal.pone.0167348. eCollection 2016.

35.

Simultaneous occurrence of spontaneous coronary artery dissections of the left anterior descending and right coronary arteries in acute myocardial infarction.

Yamamoto W, Fujii K, Otsuji S, Takiuchi S, Hasegawa K, Ishibuchi K, Kashiyama T, Tamaru H, Ishii R, Yabuki M, Ibuki M, Nagayama S, Higashino Y.

J Cardiol Cases. 2016 Dec 7;15(3):84-87. doi: 10.1016/j.jccase.2016.10.012. eCollection 2017 Mar.

36.

Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation.

Tachibana T, Matsumoto K, Tanaka M, Hagihara M, Motohashi K, Yamamoto W, Ogusa E, Koyama S, Numata A, Tomita N, Taguchi J, Fujisawa S, Kanamori H, Nakajima H.

Leuk Lymphoma. 2017 Jun;58(6):1403-1411. doi: 10.1080/10428194.2016.1243678. Epub 2016 Oct 14.

PMID:
27739916
37.

Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.

Morishita S, Hagihara M, Itabashi M, Ishii Y, Yamamoto W, Numata A, Motohashi K, Matsumoto K, Fujisawa S, Nakajima H.

Rinsho Ketsueki. 2016 Aug;57(8):999-1003. doi: 10.11406/rinketsu.57.999. Review. Japanese.

PMID:
27599415
38.

SERCA2 Deficiency Impairs Pancreatic β-Cell Function in Response to Diet-Induced Obesity.

Tong X, Kono T, Anderson-Baucum EK, Yamamoto W, Gilon P, Lebeche D, Day RN, Shull GE, Evans-Molina C.

Diabetes. 2016 Oct;65(10):3039-52. doi: 10.2337/db16-0084. Epub 2016 Aug 3.

39.

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.

Yamamoto W, Andou T, Itabashi M, Koyama S, Ishii Y, Numata A, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S.

Intern Med. 2016;55(13):1721-7. doi: 10.2169/internalmedicine.55.6094. Epub 2016 Jul 1.

40.

The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.

Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J.

Leuk Lymphoma. 2016 Dec;57(12):2763-2770. Epub 2016 Jun 20.

PMID:
27320054
41.

Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.

Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, Ito S, Tachibana T, Hagihara M, Matsumoto K, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Fujita H, Fujisawa S, Ogawa K, Ishigatsubo Y.

Leuk Lymphoma. 2017 Jan;58(1):104-109. Epub 2016 Jun 7.

PMID:
27267543
42.

Retrospective Study of Incidence and Prognostic Significance of Eosinophilia after Allogeneic Hematopoietic Stem Cell Transplantation: Influence of Corticosteroid Therapy.

Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.

Turk J Haematol. 2016 Sep 5;33(3):196-201. doi: 10.4274/tjh.2015.0047. Epub 2016 Apr 18.

43.

Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation.

Numata A, Fujisawa S, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Nakajima H.

Clin Transplant. 2016 May;30(5):485-6. doi: 10.1111/ctr.12702. Epub 2016 Mar 14. No abstract available.

PMID:
26990549
44.

Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.

Ishii Y, Itabashi M, Numata A, Yamamoto W, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S.

Intern Med. 2016;55(6):673-5. doi: 10.2169/internalmedicine.55.5644. Epub 2016 Mar 15.

45.

Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

Yamamoto W, Fujii E, Matsumoto K, Yamamoto E, Aoki J, Tanaka M, Ishigatsubo Y, Kanamori H.

Int J Hematol. 2016 Apr;103(4):444-52. doi: 10.1007/s12185-016-1941-2. Epub 2016 Jan 20.

PMID:
26791379
46.

The association between serious infection and disease outcome in patients with rheumatoid arthritis.

Iguchi-Hashimoto M, Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ishikawa M, Ito H, Yamakawa N, Terao C, Yamamoto K, Yamamoto W, Ohmura K, Mimori T.

Clin Rheumatol. 2016 Jan;35(1):213-8. doi: 10.1007/s10067-015-3143-3. Epub 2015 Dec 17.

PMID:
26676809
47.

CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.

Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Morita M, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Tanaka K, Washio I, Miyamoto N.

J Pharmacol Toxicol Methods. 2016 Mar-Apr;78:93-102. doi: 10.1016/j.vascn.2015.12.002. Epub 2015 Dec 4.

PMID:
26657830
48.

The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.

Kako S, Kanda Y, Kato J, Yamamoto W, Kato S, Onizuka M, Yokota A, Tatara R, Yokoyama H, Hagihara M, Usuki K, Gotoh M, Watanabe R, Kawai N, Saitoh T, Kanamori H, Takahashi S, Okamoto S.

Hematol Oncol. 2017 Sep;35(3):341-349. doi: 10.1002/hon.2276. Epub 2015 Dec 8.

PMID:
26643559
49.

Srv2/CAP is required for polarized actin cable assembly and patch internalization during clathrin-mediated endocytosis.

Toshima JY, Horikomi C, Okada A, Hatori MN, Nagano M, Masuda A, Yamamoto W, Siekhaus DE, Toshima J.

J Cell Sci. 2016 Jan 15;129(2):367-79. doi: 10.1242/jcs.176651. Epub 2015 Nov 24.

50.

Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.

Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.

Leuk Res. 2015 Aug 29. pii: S0145-2126(15)30368-4. doi: 10.1016/j.leukres.2015.08.016. [Epub ahead of print]

PMID:
26350140

Supplemental Content

Loading ...
Support Center